LIDDS Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

LIDDS heeft een totaal eigen vermogen van SEK7.7M en een totale schuld van SEK0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk SEK10.5M en SEK2.8M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

SEK 0

Schuld

Rente dekkingsratio	n/a
Contant	SEK 8.01m
Aandelen	SEK 7.72m
Totaal verplichtingen	SEK 2.81m
Totaal activa	SEK 10.53m

Recente financiële gezondheidsupdates

Recent updates

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

May 26

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

Dec 15

Will LIDDS (STO:LIDDS) Spend Its Cash Wisely?

Jul 19

Here's Why We're Not Too Worried About LIDDS' (STO:LIDDS) Cash Burn Situation

Mar 08

We're Not Very Worried About LIDDS' (STO:LIDDS) Cash Burn Rate

Nov 23

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( SEK9.1M ) LIDDS } overtreffen de korte termijn passiva ( SEK1.9M ).

Langlopende schulden: De kortetermijnactiva LIDDS ( SEK9.1M ) overtreffen de langetermijnschulden ( SEK900.0K ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: LIDDS is schuldenvrij.

Schuld verminderen: LIDDS had 5 jaar geleden geen schulden.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: LIDDS heeft minder dan een jaar aan cash runway op basis van de huidige vrije kasstroom.

Voorspelling contante baan: LIDDS heeft minder dan een jaar aan kasmiddelen als de vrije kasstroom blijft dalen met historische percentages van 1 % per jaar.

LIDDS Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

Will LIDDS (STO:LIDDS) Spend Its Cash Wisely?

Here's Why We're Not Too Worried About LIDDS' (STO:LIDDS) Cash Burn Situation

We're Not Very Worried About LIDDS' (STO:LIDDS) Cash Burn Rate

Recent updates

LIDDS AB (publ) to Report Fiscal Year 2024 Results on Feb 20, 2025

LIDDS AB (publ) to Report Nine Months, 2024 Results on Nov 21, 2024

LIDDS AB (publ) to Report First Half, 2024 Results on Aug 28, 2024

LIDDS AB (publ) Announces CFO Changes, Effective 1 September 2024

New major risk - Shareholder dilution

LIDDS AB (publ), Annual General Meeting, May 27, 2024

LIDDS AB (publ) (OM:LIDDS) completed the acquisition of Noviga Research AB.

LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB.

LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB.

LIDDS AB (publ) Approves Board Elections

LIDDS AB (publ) to Report Fiscal Year 2023 Final Results on Apr 23, 2024

Lidds AB (Publ) Announces Resignation of Daniel Lifveredson from Board of Directors

LIDDS AB (publ) to Report Q1, 2024 Results on May 15, 2024

First half 2023 earnings released: kr0.29 loss per share (vs kr0.58 loss in 1H 2022)

LIDDS AB (publ) Announces CEO Changes

New major risk - Financial position

First quarter 2023 earnings released: kr0.29 loss per share (vs kr0.29 loss in 1Q 2022)

Full year 2022 earnings released: kr1.07 loss per share (vs kr1.16 loss in FY 2021)

LIDDS AB (publ) to Report Fiscal Year 2022 Results on Apr 25, 2023

Third quarter 2022 earnings released: kr0.23 loss per share (vs kr0.26 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.29 loss per share (vs kr0.32 loss in 2Q 2021)

LIDDS AB (publ) to Report Fiscal Year 2022 Results on Feb 24, 2023

High number of new directors

LIDDS AB (publ) Announces CEO Changes

LIDDS Patent Covering the NanoZolid® Production Process Granted in Israel

LIDDS AB (publ) Announces Board Changes

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

First quarter 2022 earnings: EPS and revenues miss analyst expectations

LIDDS AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

No independent directors

LIDDS AB (publ) announced that it expects to receive SEK 40.8 million in funding from Nice & Green SA

LIDDS AB Next Step with Nanozolid® Formulated Docetaxel

LIDDS AB Announces Positive Topline Results from the Phase I Dose-Escalating Study of NanoZolid-Formulated Docetaxel

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

Will LIDDS (STO:LIDDS) Spend Its Cash Wisely?

Here's Why We're Not Too Worried About LIDDS' (STO:LIDDS) Cash Burn Situation

Director recently bought kr159k worth of stock

LIDDS AB (publ) Enters R&D Agreement with Potential Exclusive, Global Product License Option

New 90-day low: kr13.50

LIDDS AB (publ) and Pharmidea Signs Manufacturing Agreement

LIDDS Files Patent Application for Method to Treat Brain Cancer with Intratumoral Depot Injections

LIDDS AB (publ) Provides Update on Chinese Conditional Market Approval (CMA) for Liproca® Depot

LIDDS AB (publ) Announces Management Changes, Effective April 19, 2021

We're Not Very Worried About LIDDS' (STO:LIDDS) Cash Burn Rate

New 90-day low: kr13.00

New 90-day low: kr13.10

LIDDS AB (publ) Announces Data on Liproca Depot from Open Label Extension Study

New 90-day high: kr16.15

LIDDS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 37.083996 million.

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven